Bayer today announced that it has received regulatory authorisation for Jessico® Fusion, the first co-formulation of its new broad-spectrum Iblon® (isoflucypram) and Inatreq™ active (fenpicoxamid). Jessico® Fusion will be available to UK growers for use across a range of winter and spring sown cereals in spring 2026.
“Jessico® Fusion is the latest product to form part of the Iblon® family of fungicides all of which have demonstrated excellent efficacy against the principal foliar threats, such as Septoria leaf blotch, yellow rust and brown rust,” said Greg Hanna, Fungicide Market Development for Bayer’s Crop Science division in the UK. “The product maintains this performance, especially at the second application T2, which is where we see it delivering the greatest value to growers.”
Bayer assessed Jessico® Fusion’s activity across many seasons, including 2024 and 2025 which offered the opportunity to assess its performance under uniquely challenging conditions.
Greg Hanna added: “In both the 2024 and 2025 seasons when conditions were either extremely wet or exceptionally dry, Jessico® Fusion performed impressively, frequently delivering the greatest yield uplift of any product in trial. This suggests the active substances in Jessico® Fusion combine to deliver an excellent broad spectrum disease control solution well-suited to T2 but with the flexibility to be used at the fist application T1 in higher Septoria pressure conditions.”
The prolonged dry weather of 2025 made assessing the disease control performance of all fungicides a challenge. These conditions, however, were ideal for assessing any crop greening benefits fungicides deliver over and above what might otherwise be expected. In this situation, the Iblon component of Jessico® Fusion delivered impressively sustaining green leaf area beyond that typically seen with Ascra® Xpro® (bixafen + fluopyram + prothioconazole).
“The 2025 season provided an opportunity to assess the physiological benefits of a fungicide. The extended chlorophyll activity seen with Iblon in earlier trials was repeated with Jessico® Fusion with treated crops delivering a positive yield return in the absence of disease but under intense drought stress,” explained Hanna.
The performance of Jessico® Fusion at either the T1 or T2 timing and as part of a balanced programme was also investigated as part of Bayer’s market development trials.
The inclusion of Inatreq® in Jessico® Fusion makes T2 the obvious timing whic is supported by the trials data. In contrast, the inclusion of fluopyram and prothioconazole with Iblon® in Plaxium® give it the edge at T1. The two products deliver excellent control of the main disease threats at each timing giving growers and their agronomists the protection needed and the flexibility to apportion spend within the programme depending on priorities.
Acknowledgements:
Growers can apply a maximum of one application of Jessico® Fusion per year up to a maximum individual dose of 1.5 L/ha.
Ascra® Xpro® contains bixafen, fluopyram and prothioconazole. Jessico® Fusion contains isoflucypram (Iblon®) and fenpicoxamid (Inatreq™ active). Plaxium® contains isoflucypram, fluopyram and prothioconazole. Ascra, Iblon, Jessico, Plaxium and Xpro are registered trademarks of Bayer. Inatreq is a registered trademark of Corteva Agriscience and its affiliated companies.